The clinical presentation of TBE typically occurs in two phases. The first phase, known as the viremic phase, includes non-specific symptoms such as fever, fatigue, headache, muscle aches, and nausea. This phase lasts about 2 to 7 days and may be followed by a symptom-free interval.

The second phase, which occurs in about one-third of infected individuals, involves the central nervous system. Symptoms may include high fever, severe headache, neck stiffness, confusion, and in severe cases, seizures or paralysis. This phase can lead to encephalitis (inflammation of the brain), meningitis (inflammation of the membranes surrounding the brain and spinal cord), or meningoencephalitis (a combination of both).

Diagnosing TBE involves a combination of clinical evaluation and laboratory tests. A detailed patient history, including recent travel to endemic areas and potential tick exposure, is crucial. Laboratory confirmation is typically achieved through serological tests that detect specific antibodies against TBEV in the blood or cerebrospinal fluid (CSF). Polymerase chain reaction (PCR) tests may also be used to detect viral RNA, although they are less commonly employed due to the transient nature of viremia.

There is no specific antiviral treatment for TBE. Management is primarily supportive and focuses on relieving symptoms and preventing complications. Hospitalization may be necessary for patients with severe neurological symptoms. Supportive care includes pain management, hydration, and monitoring of neurological status. In cases of severe encephalitis, intensive care may be required.

The prognosis of TBE varies depending on the severity of the disease and the patient's age and overall health. While many individuals recover fully, some may experience long-term neurological sequelae such as cognitive impairment, balance disorders, or persistent headaches. The mortality rate is relatively low but can be higher in older adults and those with severe disease.

TBE is caused by the Tick-Borne Encephalitis Virus, a member of the Flavivirus family. The virus is primarily transmitted to humans through the bite of infected ticks, although consumption of unpasteurized dairy products from infected animals can also be a source of infection. The virus is maintained in nature through a cycle involving small mammals and ticks.

TBE is endemic in parts of Europe and Asia, with the highest incidence reported in countries such as Russia, Austria, and the Baltic states. The disease is most commonly reported during the warmer months when ticks are active. The risk of infection is higher in rural and forested areas where ticks are prevalent.

After a tick bite, TBEV enters the bloodstream and initially replicates in local tissues. The virus then spreads to the central nervous system, where it can cause inflammation and damage to brain tissues. The immune response to the virus contributes to the symptoms and severity of the disease.

Preventing TBE involves avoiding tick bites and vaccination. Protective measures include wearing long sleeves and pants, using insect repellent, and performing tick checks after outdoor activities. Vaccination is available and recommended for individuals living in or traveling to endemic areas, especially those at higher risk of exposure.

Tick-Borne Encephalitis is a viral infection transmitted by ticks, leading to a biphasic illness with potential neurological complications. Diagnosis is based on clinical presentation and serological testing. While there is no specific treatment, supportive care is essential. Prevention through vaccination and tick avoidance is crucial, especially in endemic regions.

If you suspect you have been exposed to ticks in an area where TBE is common, monitor for symptoms such as fever, headache, and fatigue. If neurological symptoms develop, seek medical attention promptly. Preventive measures, including vaccination and tick avoidance, are key to reducing the risk of TBE.